HEPATITIS B， CHRONIC
Clinical trials for HEPATITIS B， CHRONIC explained in plain language.
Never miss a new study
Get alerted when new HEPATITIS B， CHRONIC trials appear
Sign up with your email to follow new studies for HEPATITIS B， CHRONIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to cure hepatitis b without lifelong pills
Disease control CompletedThis Phase 3 trial tests a drug called bepirovirsen in nearly 1,000 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough that participants can safely stop all hepatitis B medications and re…
Matched conditions: HEPATITIS B， CHRONIC
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug aims to free hepatitis b patients from daily pills
Disease control CompletedThis Phase 3 study tests bepirovirsen, an experimental drug, in 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough to allow patients to stop all hepatitis B treatments and remain viru…
Matched conditions: HEPATITIS B， CHRONIC
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New injection aims to tame chronic hepatitis b
Disease control CompletedThis study tests an experimental drug called AHB-137 in healthy volunteers and people with chronic hepatitis B who are already on antiviral medication. The goal is to check if the drug is safe and shows early signs of controlling the virus. About 129 participants will receive eit…
Matched conditions: HEPATITIS B， CHRONIC
Phase: PHASE1, PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for hepatitis b: experimental combo aims to clear the virus
Disease control CompletedThis study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…
Matched conditions: HEPATITIS B， CHRONIC
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hepatitis b: experimental combo aims to silence the virus
Disease control CompletedThis early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The s…
Matched conditions: HEPATITIS B， CHRONIC
Phase: PHASE1, PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New Two-Drug combo aims to tame chronic hepatitis b
Disease control CompletedThis completed phase 2 study tested a two-step treatment for chronic hepatitis B. First, participants received an antisense drug (bepirovirsen) for 12 or 24 weeks, followed by a targeted immunotherapy. The goal was to see if this sequence could safely improve virus control beyond…
Matched conditions: HEPATITIS B， CHRONIC
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New cocktail of drugs shows promise in hepatitis b trial
Disease control CompletedThis study tested several new drug combinations in 281 people with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if adding experimental drugs could clear a key virus marker (HBsAg) from the blood. Participants received different combinati…
Matched conditions: HEPATITIS B， CHRONIC
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 26, 2026 18:59 UTC